Last edition
News about "masupirdine "
Suven Completes Phase 3 Enrollment of Masupirdine for Alzheimer's-Related Agitation
Suven Life Sciences completes enrollment in its global Phase 3 masupirdine trial, with 424 patients randomised to evaluate the therapy for agitation associated with Alzheimer’s dementia.
Masupirdine | 05/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members